Preferred Label : Anti-HER2-STING Agonist ADC XMT-2056;
NCIt synonyms : HER2-targeted STING Agonist ADC XMT-2056; STING Agonist ADC XMT-2056; Anti-HER2-STING Agonist Antibody-drug Conjugate XMT-2056;
NCIt definition : An antibody-drug conjugate (ADC) composed of HT-19, a monoclonal antibody directed
against the tumor-associated antigen (TAA) human epidermal growth factor receptor
2 (EGFR2; HER2; ErbB2), linked to a payload composed of an agonist for the stimulator
of interferon genes protein (STING; transmembrane protein 173; TMEM173), with potential
immuno-activating and antineoplastic activities. Upon intravenous administration of
anti-HER2 STING agonist ADC XMT-2056, the anti-HER2 antibody moiety targets and binds
to HER2 while the STING agonist targets and binds to STING on immune cells in the
tumor microenvironment (TME). This allows for specific activation of the STING pathway
in the TME. This leads to the production of pro-inflammatory cytokines, including
interferons (IFNs), enhances the cross-presentation of tumor-associated antigens (TAAs)
by dendritic cells (DCs), and induces a cytotoxic T-lymphocyte (CTL)-mediated immune
response against cancer cells. STING, a transmembrane protein that activates immune
cells in the TME, plays a key role in the activation of the innate immune system.
The conjugation of the anti-HER2 antibody to the STING agonist improves targeted delivery
of the STING agonist and increases tumor exposure and enhances the STING-mediated
anti-tumor immune responses while limiting systemic toxicity.;
Molecule name : XMT-2056; XMT 2056;
NCI Metathesaurus CUI : CL1799031;
Origin ID : C190297;
UMLS CUI : C5783614;
Semantic type(s)
- concept_is_in_subset
- has_target
